Related Experiment Video
Updated: May 5, 2026
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
25.1K
[DBS therapy for Parkinson's disease - our approach]
Sumito Sato1, Yoko Takiyama, Yutaka Ogino
1Department of Neurosurgery, Kitasato University School of Medicine.
Rinsho Shinkeigaku = Clinical Neurology
|December 3, 2013
Summary
The study suggests globus pallidus interna deep brain stimulation (GPi-DBS) for Parkinson's disease patients at risk of cognitive decline. Monkey research indicates subthalamic nucleus (STN) stimulation may cause emotional side effects.
Area of Science:
- Neuroscience
- Neurosurgery
- Neurology
Context:
- Deep brain stimulation (DBS) is a key therapy for Parkinson's disease (PD).
- The choice between targeting the subthalamic nucleus (STN) or globus pallidus interna (GPi) for DBS remains controversial.
- Patient selection is crucial, especially for those at risk of cognitive decline.
Purpose:
- To investigate the optimal target for DBS in Parkinson's disease patients, considering cognitive outcomes.
- To evaluate the potential adverse emotional effects of STN-DBS by examining its limbic connections in non-human primates.
- To explore the physiological mechanisms of GPi-DBS and its impact on information processing.
Summary:
- This study advocates for GPi-DBS in Parkinson's patients identified as high-risk for cognitive decline post-STN-DBS, based on cognitive function assessments.
- Monkey experiments suggest that stimulating the medial STN could lead to adverse emotional effects due to its limbic cortical inputs.
- Further primate research indicates that high-frequency GPi stimulation effectively disrupts information flow within the GPi.
Impact:
- Provides evidence to guide the selection of DBS targets in Parkinson's disease, potentially improving patient outcomes.
- Highlights the risk of emotional side effects associated with STN-DBS, informing surgical decision-making.
- Offers insights into the neural mechanisms underlying GPi-DBS efficacy in managing Parkinson's disease symptoms.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:24Parkinson Disease l: Introduction
28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
01:24Parkinson Disease ll: Pathophysiology
34
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
34
01:28Drug Therapy
450
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
450
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K